Experts Say Biosimilars Will Perform Under Trump


Stacie Ropka, an intellectual property attorney with Axinn Veltrop & Harkrider, talked to Biopharma-Reporter about how biosimilars would perform under Trump. Ropka believed that Trump’s criticism of high drug prices would lead to him favoring the approval of biosimilars during his tenure. A greater number of biosimilar filings are expected with the FDA this year, including biosimilar drugs from Roche, Amgen, Mylan, and Samsung.

Read the source article at BioPharmaReporter

About the Author

Related Posts

Leave a Reply